A phase 2, randomized, double‐blind, vehicle‐controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17587 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Atsuyuki Igarashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Igarashi Dermatology Higashigotanda, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Resorcinols. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Tobacco Inc..
Abstract (Originalsprache)
Tapinarof is a nonsteroidal, topical, aryl hydrocarbon receptor agonist approved for the treatment of atopic dermatitis (AD) in Japanese patients aged ≥12 years. We evaluated the efficacy and safety of tapinarof in Japanese pediatric patients aged 2 to 11 years with AD in a phase 2, multicenter, randomized, double‐blind, vehicle‐controlled trial. Eligible patients ( N = 121) were randomized 1:1:1 to receive tapinarof cream 0.5%, tapinarof cream 1%, or vehicle cream once daily for 8 weeks. At week 8, the least‐squares mean percent change from baseline in Eczema Area and Severity Index (EASI) score (the primary endpoint) was −81.29% in the tapinarof 0.5% group, −77.62% in the tapinarof 1% group, and − 18.56% in the vehicle group. Reductions in EASI score at week 8 were significantly greater in the tapinarof groups than in the vehicle group ( p < 0.0001 for both comparisons). The proportion of patients with ≥75% improvement from baseline in EASI score at week 8 was 77.5% in the tapinarof 0.5% group, 70.7% in the tapinarof 1% group, and 15.0% in the vehicle group. The proportion of patients who achieved an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear) with ≥2‐grade improvement from baseline at week 8 was 32.5% in the tapinarof 0.5% group, 43.9% in the tapinarof 1% group, and 17.5% in the vehicle group. No treatment‐related serious adverse events (AEs) were reported; all of the AEs were mild or moderate. Common AEs in tapinarof‐treated patients included gastroenteritis, application site irritation, and nasopharyngitis. The incidence of trial discontinuations due to AEs was low in tapinarof‐treated patients (one patient for each strength). In summary, both strengths of tapinarof cream demonstrated greater efficacy than vehicle cream and were well tolerated in Japanese pediatric patients with AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Igarashi Dermatology Higashigotanda, Tokyo, Japan.
- Research and Clinical Center for Yusho and Dioxin, Kyushu University, Fukuoka, Japan.
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Japan Tobacco Inc, Tokyo, Japan.
ORCID-Profile: Shuichi Fukasawa
Förderung
- Japan Tobacco Inc.
Zitieren
APA
Igarashi, A., Tsuji, G., Murata, R., Fukasawa, S., & Yamane, S. (2025). A phase 2, randomized, double‐blind, vehicle‐controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17587
Vancouver
Igarashi A, Tsuji G, Murata R, Fukasawa S, Yamane S. A phase 2, randomized, double‐blind, vehicle‐controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17587
BibTeX
@article{Igarashi2025,
author = {Igarashi, Atsuyuki and Tsuji, Gaku and Murata, Ryusei and Fukasawa, Shuichi and Yamane, Satoshi},
title = {A phase 2, randomized, double‐blind, vehicle‐controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17587}
}
EUVIMED